Supriya Lifescience Ltd
☆ Add to Watchlist
Investing Reference
Trading Reference
AI Probability Statement
Probability Statement
Supriya Lifescience Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, it could see significant upside potential. However, if it falls below the support, downside risk increases.
Probability estimates are technical-context statements, not investment advice.
More Options
Business Overview
Supriya Lifescience Ltd is a leading Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients (APIs) and intermediates. Catering primarily to the global pharmaceutical industry, it plays a crucial role in ensuring the availability of essential medicines. The company's commitment to quality, innovation, and sustainability positions it as a trusted partner for healthcare providers and manufacturers alike. With a strong focus on research and development, Supriya Lifescience is dedicated to enhancing healthcare outcomes and contributing to the well-being of society.
- Leading manufacturer of APIs in India
- Strong focus on quality and compliance
- Robust R&D capabilities driving innovation
- Sustainable practices in production
- Trusted partner for global pharmaceutical companies
Investment Thesis
Supriya Lifescience Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning in the market make it a noteworthy addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment offers substantial growth runway.
- Valuation metrics are attractive compared to industry peers, indicating potential upside.
- Robust financial performance and consistent revenue growth support long-term prospects.
- Strategic investments in R&D position the company for future innovations.
Opportunity vs Risk
- Growing demand for pharmaceutical products
- Expansion into international markets
- Strong R&D capabilities
- Government support for healthcare sector
- Regulatory changes affecting operations
- Intense competition in the industry
- Dependence on key customers
- Fluctuating raw material prices
Peer Perspective
Supriya Lifescience Ltd trades at a discount to peers like Aarti Drugs and Divi's Laboratories, suggesting potential upside. A sustained improvement in margins and consistent growth could trigger a favorable rerating.
Future Outlook
Supriya Lifescience Ltd is well-positioned for growth, driven by strong demand in the pharmaceutical sector. Successful execution of its strategic initiatives and effective cost control will be crucial to maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Supriya Lifescience Ltd do?A: Supriya Lifescience Ltd is a pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and formulations.
- Q: Is Supriya Lifescience Ltd listed on stock exchanges?A: Yes, Supriya Lifescience Ltd is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
- Q: What are the key products of Supriya Lifescience Ltd?A: The company primarily produces APIs for various therapeutic segments, including analgesics and anti-allergics.
- Q: How can I invest in Supriya Lifescience Ltd?A: You can invest through a stockbroker or online trading platform by purchasing shares.
- Q: What factors should I consider before investing?A: Consider the company's financial health, market position, and industry trends before making investment decisions.
-
10BusinessHighThe sector is growing with increasing demand for pharmaceutical products, but competition is high.
-
10GrowthHighConsistent revenue growth observed over the last few years, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is not consistently higher than net profit.
-
8ValuationHighP/E and P/B ratios are higher than industry averages, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios could be improved.
-
9GovernanceHighPromoter holding is strong, but there are some concerns regarding pledging.
-
10DriversHighGrowth drivers are present, but execution risks remain due to market volatility.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity affecting price action.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100